NasdaqGS - Nasdaq Real Time Price • USD
Codexis, Inc. (CDXS)
As of 12:49 PM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 7 | 6 |
Avg. Estimate | -0.18 | -0.2 | -0.65 | -0.68 |
Low Estimate | -0.22 | -0.22 | -0.74 | -0.83 |
High Estimate | -0.14 | -0.18 | -0.57 | -0.53 |
Year Ago EPS | -0.34 | -0.17 | -1.12 | -0.65 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 7 | 6 |
Avg. Estimate | 13.81M | 12.98M | 65.38M | 62.05M |
Low Estimate | 11.79M | 11.39M | 58.88M | 51M |
High Estimate | 15M | 15.2M | 71M | 72.5M |
Year Ago Sales | 12.98M | -- | 70.14M | 65.38M |
Sales Growth (year/est) | 6.40% | -- | -6.80% | -5.10% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.31 | -0.21 | -0.32 | -0.12 |
EPS Actual | -0.34 | -0.17 | -0.5 | -0.1 |
Difference | -0.03 | 0.04 | -0.18 | 0.02 |
Surprise % | -9.70% | 19.00% | -56.20% | 16.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.18 | -0.2 | -0.65 | -0.68 |
7 Days Ago | -0.18 | -0.2 | -0.65 | -0.68 |
30 Days Ago | -0.18 | -0.2 | -0.65 | -0.68 |
60 Days Ago | -0.19 | -0.17 | -0.67 | -0.59 |
90 Days Ago | -0.19 | -0.17 | -0.67 | -0.59 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | CDXS | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 47.10% | -- | -- | 1.50% |
Next Qtr. | -17.60% | -- | -- | 12.10% |
Current Year | 42.00% | -- | -- | 4.40% |
Next Year | -4.60% | -- | -- | 13.20% |
Next 5 Years (per annum) | 15.00% | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Upgrade | Benchmark: Hold to Buy | 2/29/2024 |
Downgrade | Benchmark: Buy to Hold | 11/7/2023 |
Maintains | Piper Sandler: Overweight to Overweight | 11/6/2023 |
Reiterates | Benchmark: Buy to Buy | 9/1/2023 |
Maintains | Stifel: Buy to Buy | 8/14/2023 |
Reiterates | Stephens & Co.: Overweight to Overweight | 7/21/2023 |
Related Tickers
NRXP NRx Pharmaceuticals, Inc.
3.3300
+6.05%
CRBU Caribou Biosciences, Inc.
3.7400
-0.53%
TSHA Taysha Gene Therapies, Inc.
2.3850
+3.70%
EYEN Eyenovia, Inc.
0.6800
-4.40%
PRQR ProQR Therapeutics N.V.
1.9799
+1.03%
CDTX Cidara Therapeutics, Inc.
13.10
+0.77%
PTN Palatin Technologies, Inc.
1.7300
+0.58%
CLRB Cellectar Biosciences, Inc.
3.0450
+0.83%
WVE Wave Life Sciences Ltd.
4.6900
-1.05%
GALT Galectin Therapeutics Inc.
3.5800
+2.29%